Literature DB >> 16491127

Involvement of adaptor protein Crk in malignant feature of human ovarian cancer cell line MCAS.

H Linghu1, M Tsuda, Y Makino, M Sakai, T Watanabe, S Ichihara, H Sawa, K Nagashima, N Mochizuki, S Tanaka.   

Abstract

Signaling adaptor protein Crk regulates cell motility and growth through its targets Dock180 and C3G, those are the guanine-nucleotide exchange factors (GEFs) for small GTPases Rac and Rap, respectively. Recently, overexpression of Crk has been reported in various human cancers. To define the role for Crk in human cancer cells, Crk expression was targeted in the human ovarian cancer cell line MCAS through RNA interference, resulting in the establishment of three Crk knockdown cell lines. These cell lines exhibited disorganized actin fibers, reduced number of focal adhesions, and abolishment of lamellipodia formation. Decreased Rac activity was demonstrated by pull-down assay and FRET-based time-lapse microscopy, in association with suppression of both motility and invasion by phagokinetic track assay and transwell assay in these cells. Furthermore, Crk knockdown cells exhibited slow growth rates in culture and suppressed anchorage-dependent growth in soft agar. Tumor forming potential in nude mice was attenuated, and intraperitoneal dissemination was not observed when Crk knockdown cells were injected into the peritoneal cavity. These results suggest that the Crk is a key component of focal adhesion and involved in cell growth, invasion, and dissemination of human ovarian cancer cell line MCAS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16491127     DOI: 10.1038/sj.onc.1209398

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  23 in total

1.  Domain cooperativity in multidomain proteins: what can we learn from molecular alignment in anisotropic media?

Authors:  Tairan Yuwen; Carol Beth Post; Nikolai R Skrynnikov
Journal:  J Biomol NMR       Date:  2011-09-27       Impact factor: 2.835

2.  Phosphorylation of Crk on tyrosine 251 in the RT loop of the SH3C domain promotes Abl kinase transactivation.

Authors:  G Sriram; C Reichman; A Tunceroglu; N Kaushal; T Saleh; K Machida; B Mayer; Q Ge; J Li; P Hornbeck; C G Kalodimos; R B Birge
Journal:  Oncogene       Date:  2011-05-23       Impact factor: 9.867

3.  The role of Crk/Dock180/Rac1 pathway in the malignant behavior of human ovarian cancer cell SKOV3.

Authors:  Hui Wang; Hua Linghu; Jin Wang; Ya-ling Che; Ting-xiu Xiang; Wei-xue Tang; Zhen-wei Yao
Journal:  Tumour Biol       Date:  2009-12-23

4.  Fibroblast Growth Requires CT10 Regulator of Kinase (Crk) and Crk-like (CrkL).

Authors:  Taeju Park; Mateusz Koptyra; Tom Curran
Journal:  J Biol Chem       Date:  2016-11-02       Impact factor: 5.157

5.  miR-23a promotes invasion of glioblastoma via HOXD10-regulated glial-mesenchymal transition.

Authors:  Kazuhiro Yachi; Masumi Tsuda; Shinji Kohsaka; Lei Wang; Yoshitaka Oda; Satoshi Tanikawa; Yusuke Ohba; Shinya Tanaka
Journal:  Signal Transduct Target Ther       Date:  2018-12-28

6.  Roles for crk in cancer metastasis and invasion.

Authors:  Masumi Tsuda; Shinya Tanaka
Journal:  Genes Cancer       Date:  2012-05

7.  Models of crk adaptor proteins in cancer.

Authors:  Emily S Bell; Morag Park
Journal:  Genes Cancer       Date:  2012-05

8.  Proteins that bind the Src homology 3 domain of CrkI have distinct roles in Crk transformation.

Authors:  J Zheng; K Machida; S Antoku; K Y Ng; K P Claffey; B J Mayer
Journal:  Oncogene       Date:  2010-08-23       Impact factor: 9.867

9.  Binding Mechanism of the N-Terminal SH3 Domain of CrkII and Proline-Rich Motifs in cAbl.

Authors:  Veer S Bhatt; Danyun Zeng; Inna Krieger; James C Sacchettini; Jae-Hyun Cho
Journal:  Biophys J       Date:  2016-06-21       Impact factor: 4.033

10.  Crk and CrkL adaptor proteins: networks for physiological and pathological signaling.

Authors:  Raymond B Birge; Charalampos Kalodimos; Fuyuhiko Inagaki; Shinya Tanaka
Journal:  Cell Commun Signal       Date:  2009-05-10       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.